1. Home
  2. KKR vs SNY Comparison

KKR vs SNY Comparison

Compare KKR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KKR
  • SNY
  • Stock Information
  • Founded
  • KKR 1976
  • SNY 1994
  • Country
  • KKR United States
  • SNY France
  • Employees
  • KKR N/A
  • SNY N/A
  • Industry
  • KKR Investment Managers
  • SNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • KKR Finance
  • SNY Health Care
  • Exchange
  • KKR Nasdaq
  • SNY Nasdaq
  • Market Cap
  • KKR 120.1B
  • SNY 116.1B
  • IPO Year
  • KKR 2010
  • SNY N/A
  • Fundamental
  • Price
  • KKR $118.33
  • SNY $50.58
  • Analyst Decision
  • KKR Strong Buy
  • SNY Buy
  • Analyst Count
  • KKR 17
  • SNY 4
  • Target Price
  • KKR $154.00
  • SNY $61.50
  • AVG Volume (30 Days)
  • KKR 4.5M
  • SNY 2.7M
  • Earning Date
  • KKR 11-07-2025
  • SNY 10-24-2025
  • Dividend Yield
  • KKR 0.63%
  • SNY 3.16%
  • EPS Growth
  • KKR N/A
  • SNY 105.93
  • EPS
  • KKR 2.11
  • SNY 8.67
  • Revenue
  • KKR $21,419,978,000.00
  • SNY $53,890,648,839.00
  • Revenue This Year
  • KKR N/A
  • SNY $1.40
  • Revenue Next Year
  • KKR $32.13
  • SNY $6.67
  • P/E Ratio
  • KKR $56.07
  • SNY $11.50
  • Revenue Growth
  • KKR N/A
  • SNY N/A
  • 52 Week Low
  • KKR $86.15
  • SNY $44.62
  • 52 Week High
  • KKR $170.40
  • SNY $60.12
  • Technical
  • Relative Strength Index (RSI)
  • KKR 37.78
  • SNY 56.17
  • Support Level
  • KKR $119.74
  • SNY $50.54
  • Resistance Level
  • KKR $124.23
  • SNY $51.64
  • Average True Range (ATR)
  • KKR 3.94
  • SNY 0.70
  • MACD
  • KKR 0.26
  • SNY 0.05
  • Stochastic Oscillator
  • KKR 23.60
  • SNY 55.74

About KKR KKR & Co. Inc.

KKR is one of the world's largest alternative asset managers, with $664.3 billion in total managed assets, including $526.0 billion in fee-earning AUM, at the end of March 2025. The company has two core segments: asset management (which includes private markets—private equity, credit, infrastructure, energy, and real estate—and public markets—primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: